DexCom Research and Development Expenses 2010-2024 | DXCM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

DexCom annual research and development expenses for 2024 were $0.552B, a 9.21% increase from 2023.
DexCom annual research and development expenses for 2023 were $0.506B, a 4.46% increase from 2022.
DexCom annual research and development expenses for 2022 were $0.484B, a 19.86% decline from 2021.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

DexCom annual research and development expenses for 2024 were $0.552B, a 9.21% increase from 2023.
DexCom annual research and development expenses for 2023 were $0.506B, a 4.46% increase from 2022.
DexCom annual research and development expenses for 2022 were $0.484B, a 19.86% decline from 2021.

Related Stocks
Company Name	Market Cap
Intuitive Surgical (ISRG)	$216B
Thermo Fisher Scientific (TMO)	$205.7B
Alcon (ALC)	$44.2B
Edwards Lifesciences (EW)	$44.1B
IDEXX Laboratories (IDXX)	$37.1B
IQVIA Holdings (IQV)	$34.2B
Mettler-Toledo (MTD)	$27.3B
Waters (WAT)	$22.6B
STERIS (STE)	$21.7B
SONOVA HOLDING (SONVY)	$19.3B
Hologic (HOLX)	$14.4B
Fresenius Medical Care AG KGaA (FMS)	$13.5B
Penumbra (PEN)	$11.7B
Sysmex ADR (SSMXY)	$11.5B
Globus Medical (GMED)	$11.5B
Masimo (MASI)	$9.5B
Glaukos (GKOS)	$8.7B
Teleflex (TFX)	$8.1B
Inari Medical (NARI)	$4.7B
Integer Holdings (ITGR)	$4.5B
PROCEPT BioRobotics (PRCT)	$3.4B
Veracyte (VCYT)	$3.2B
Nihon Kohden (NHNKY)	$2.7B
LivaNova (LIVN)	$2.6B
TransMedics (TMDX)	$2.5B
Elekta AB (EKTAY)	$2.3B
Tandem Diabetes Care (TNDM)	$2.1B
Integra LifeSciences Holdings (IART)	$1.7B
Alphatec Holdings (ATEC)	$1.5B
Pulse Biosciences (PLSE)	$1.2B